The late-stage ACHIEVE-3 study compared two doses of orforglipron with Novo Nordisk’s oral semaglutide, sold for diabetes as Rybelsus, over 52 weeks. At the highest tested dose, orforglipron cut A1C by 2.2 percentage points, compared with a 1.4-point reduction for oral semaglutide. Patients on the higher orforglipron dose lost an average 19.7lb, or 9.2 per cent of body weight, while those on the higher oral semaglutide dose lost 11lb, or 5.3 per cent.
The results mark an important moment in the fast-expanding GLP-1 market, where weekly injections such as Ozempic, Wegovy, Mounjaro and Zepbound have reshaped treatment for diabetes and obesity but remain constrained by cost, supply, cold-chain needs and patient resistance to injections. Orforglipron is designed as a small-molecule GLP-1 receptor agonist, allowing it to be taken as a standard tablet without refrigeration and without the strict fasting requirements attached to oral semaglutide.
The trial enrolled 1,698 adults with type 2 diabetes across several countries and tested orforglipron doses of 12mg and 36mg against oral semaglutide doses of 7mg and 14mg. The study met its primary goal and showed superiority on key measures of glycaemic control and weight reduction. At the lower-dose comparison, orforglipron also produced stronger A1C and weight-loss outcomes than oral semaglutide.
The convenience profile is central to Lilly’s commercial argument. Oral semaglutide must be taken on an empty stomach with a small amount of water, followed by a waiting period before food, drink or other medicines. Orforglipron can be taken with or without meals, a feature that could improve adherence in routine clinical use, especially in markets where daily schedules, work patterns and access to medical counselling vary widely.
Safety remains a critical test. Gastrointestinal side effects, including nausea, diarrhoea, vomiting and constipation, were the most common adverse events, broadly consistent with the GLP-1 drug class. Discontinuation rates were higher at stronger doses, underlining the trade-off between efficacy and tolerability that has shaped the obesity-drug market since GLP-1 medicines became mainstream. Longer follow-up will be needed to assess durability of weight loss, cardiovascular outcomes and real-world adherence.
The findings intensify competition between Lilly and Novo Nordisk, the two dominant players in metabolic disease therapies. Novo Nordisk built the early lead with semaglutide, while Lilly has gained ground through tirzepatide, the active ingredient in Mounjaro and Zepbound, which targets both GLP-1 and GIP receptors. Orforglipron gives Lilly a potential oral product that could reach patients who do not want injections or cannot access cold-chain distribution.
The market opportunity is large. More than one billion people globally are estimated to live with obesity, while diabetes prevalence continues to rise across high-income and emerging economies. Demand for GLP-1 medicines has already stretched supply chains, pushed manufacturers into multibillion-dollar capacity expansions and drawn scrutiny from insurers and public health systems over affordability.
A tablet that is cheaper to manufacture could widen access, though final pricing will determine how far that promise extends. Small-molecule pills are generally easier to produce at scale than peptide-based injectable drugs, and they may be simpler to distribute in low- and middle-income markets. That advantage could be significant if regulators approve orforglipron for both diabetes and weight management.
Lilly has been building manufacturing capacity ahead of potential approvals, while Novo Nordisk is defending its position with higher-dose oral semaglutide for obesity and broader production of injectable Wegovy. Other developers, including Pfizer, Roche, AstraZeneca-linked programmes and China-based drugmakers, are also pursuing oral obesity medicines, making pills the next major battleground in metabolic care.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
